GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » COGS-to-Revenue

Lee's Pharmaceutical Holdings (STU:L1PA) COGS-to-Revenue : 0.46 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings COGS-to-Revenue?

Lee's Pharmaceutical Holdings's Cost of Goods Sold for the six months ended in Dec. 2024 was €41.6 Mil. Its Revenue for the six months ended in Dec. 2024 was €91.1 Mil.

Lee's Pharmaceutical Holdings's COGS to Revenue for the six months ended in Dec. 2024 was 0.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lee's Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2024 was 54.31%.

Lee's Pharmaceutical Holdings COGS-to-Revenue Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings COGS-to-Revenue Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.36 0.37 0.48 0.46

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.44 0.51 0.47 0.46

Lee's Pharmaceutical Holdings COGS-to-Revenue Calculation

Lee's Pharmaceutical Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=79.44 / 171.993
=0.46

Lee's Pharmaceutical Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=41.631 / 91.112
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings  (STU:L1PA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lee's Pharmaceutical Holdings's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 41.631 / 91.112
=54.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lee's Pharmaceutical Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:00239 HKSE:03737 HKSE:08049 HKSE:03839 HKSE:00897 HKSE:00455 HKSE:01011 HKSE:01652 HKSE:08329 HKSE:00575 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
00950:Hong Kong
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Website
https://www.leespharm.com
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines